PT-141 (bremelanotide) is the only peptide in the buying guides cluster with an FDA-approved counterpart — sold as Vyleesi for hypoactive sexual desire disorder since 2019 — while simultaneously available as a research-grade compound at a fraction of the cost, with none of the manufacturing standards. It is also a cyclic peptide, introducing verification challenges that do not exist for linear compounds.
This article applies 7 verification checks to PT-141 using data from Peptigrity's independent lab tests, community reviews, and reviewed peptide shops. Peptigrity does not sell peptides or recommend vendors.
What Is PT-141 and Why Does It Have an FDA-Approved Counterpart?
PT-141 (bremelanotide) is a cyclic heptapeptide melanocortin receptor agonist (Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH, MW ~1,025.2 Da) that activates MC3R and MC4R in the hypothalamus and limbic system — the only research peptide that targets sexual arousal through central nervous system pathways rather than peripheral vascular mechanisms.
The compound was derived from Melanotan II at the University of Arizona, engineered to maximise MC3R/MC4R activation (CNS sexual arousal) while reducing MC1R activity (skin pigmentation). The mechanism is fundamentally different from PDE5 inhibitors such as sildenafil or tadalafil: those compounds act downstream on penile vascular smooth muscle. PT-141 acts upstream in the brain's desire circuitry — triggering dopamine release in the medial preoptic area of the hypothalamus.
Human clinical data is unusually robust for a research peptide. The study "PT-141: a melanocortin agonist for the treatment of sexual dysfunction" (Molinoff et al., Ann NY Acad Sci 2003) demonstrated dose-dependent erectile response in men via central melanocortin activation. A comprehensive review of melanocortin receptors and penile erection (PMC2694735) documented that PT-141 activated hypothalamic neurons shown by c-Fos immunoreactivity in the same region receiving innervation from the corpus cavernosum. Multiple Phase 2/3 trials led to FDA approval in 2019 as Vyleesi for HSDD (hypoactive sexual desire disorder) in premenopausal women.
Research-grade PT-141 from RUO vendors: same molecule, no manufacturing standards. $30–80 for 10 mg versus Vyleesi at approximately $1,000 per dose by prescription. Vyleesi has specific approved indications, dosing protocols, and safety monitoring. Research-grade PT-141 has none of this.
Regulatory status: PT-141 is NOT on FDA Category 2. WADA prohibits it under S0 (unapproved substances).
PT-141-Specific Buying Risks
PT-141 carries 3 buying risks that don't apply to linear peptides: cyclisation verification (the lactam bridge must be confirmed), Melanotan II substitution (the parent compound is cheaper with near-identical MW), and a narrow MW gap that challenges standard MS resolution.
Cyclic peptide verification. PT-141 is a cyclic heptapeptide — the lactam bridge between Asp and Lys creates the ring structure essential for receptor binding and biological activity. If cyclisation fails during synthesis, the linear precursor has the same molecular weight but different receptor binding, different HPLC retention time, and different biological activity. Standard MS confirms MW but cannot verify whether the peptide is correctly cyclised. HPLC differentiates cyclic from linear forms by retention time.
Melanotan II substitution. Melanotan II is the parent compound from which PT-141 was derived. It is cheaper to produce and more widely available. Melanotan II has broader melanocortin activity including MC1R — producing skin pigmentation (tanning) effects that PT-141 was specifically designed to minimise. The MW difference is approximately 1 Da (PT-141 ~1,025.2 Da vs Melanotan II ~1,024.2 Da with C-terminal amide). Standard-resolution MS may not distinguish them confidently. HPLC is more reliable for this specific pair.
HPLC matters more than MS for PT-141. Both the cyclic/linear distinction and the PT-141/Melanotan II distinction require chromatographic separation. For PT-141, HPLC is more informative than MS identity — the opposite emphasis from GLP-1 buying guides where MS catches substitution of compounds with large MW differences.
7 Things to Check Before Ordering PT-141
The same 7 checks apply — with heightened emphasis on HPLC for PT-141, because the cyclic/linear distinction and the narrow MW gap with Melanotan II both require chromatographic separation rather than mass-only confirmation.
1. Third-Party HPLC Purity (≥98%)
HPLC is the critical analytical method for PT-141. It separates the correctly cyclised product from the linear precursor, from Melanotan II, and from synthesis impurities — all of which standard-resolution MS may not differentiate. Cross-reference on peptigrity.com/lab-tests — filter by "PT-141." The study "Peptide Impurities in Commercial Synthetic Peptides" (PMC2238048) demonstrated that contamination at 1% produced measurable biological effects.
2. Mass Spectrometry Identity (~1,025.2 Da)
MS confirms the compound is a melanocortin heptapeptide and not a structurally unrelated compound. However, PT-141 (~1,025.2 Da) and Melanotan II (~1,024.2 Da) differ by approximately 1 Da — standard-resolution MS may not resolve this confidently. HPLC is more reliable for distinguishing PT-141 from Melanotan II specifically. MS remains useful for excluding non-melanocortin compounds. See Mass Spectrometry for Peptides: Verifying Identity & Molecular Weight for the methodology.
3. CoA From a Named, Verifiable Lab
Verify through the lab's portal: Janoshik (Task #), Chromate (QR code + Job Number), Freedom Diagnostics (online system). For PT-141: confirm the CoA reports both HPLC purity and MW. Ideally, the HPLC chromatogram should show a single major peak at the retention time consistent with the cyclic form. See Red Flags in Peptide Certificates of Analysis for the fraud detection checklist.
4. Independent Data on Peptigrity
Search peptigrity.com/lab-tests for the vendor + PT-141. Check the shop's profile on peptigrity.com/shops — trust score, ✓ Lab Verified badge, and test count. Independent community-submitted data carries more weight than vendor-published CoAs.
5. Community Reviews
Read reviews on the vendor's Peptigrity page. Each includes 5 sub-ratings: Quality, Delivery, Pricing, Customer Service, and Product Accuracy. PT-141 is one of the more subjectively evaluated peptides — community feedback on product accuracy and consistency is particularly informative.
6. Vial Presentation and Storage
Lyophilised PT-141 should be a white to off-white powder. Not lipidated — standard storage profile. Most RUO vendors ship at ambient temperature. For 2–5 day domestic transit of lyophilised powder, this is acceptable. Store at −20°C on arrival, protected from light. After reconstitution: 2–8°C, use promptly — cyclic peptides can be less stable in solution than linear peptides. 28-day reconstituted shelf life is standard.
7. Pricing Reality Check
Research-grade PT-141 pricing (March 2026):
10 mg vial: $30–80.
Vyleesi (prescription bremelanotide): ~$1,000/dose.
Below $20 for 10 mg is suspicious. If PT-141 and Melanotan II are priced identically at the same vendor and PT-141 is at the low end, substitution risk increases — Melanotan II is cheaper to produce. See Peptide Purity Standards: What Percentage Is Actually Acceptable? for the quality-price framework.
PT-141 on Peptigrity's Lab Test Database
Filter by PT-141 at peptigrity.com/lab-tests to compare independent purity data across vendors before ordering.
Community-submitted data from third-party laboratories represents real products from real buyers. Use the data before ordering. Browse the PT-141 peptide guide for the compound profile alongside lab data.
PT-141 vs Melanotan II: Different Compounds, Different Risks
PT-141 is the deamidated derivative of Melanotan II — engineered for selective central melanocortin activation without the skin pigmentation effects driven by MC1R.
Melanotan II is the parent compound: a cyclic heptapeptide with broader melanocortin receptor activity across MC1R through MC5R. Its MC1R activation produces skin darkening (tanning) — an effect that PT-141 was specifically designed to minimise. PT-141 retains the MC3R/MC4R activation responsible for CNS sexual arousal while reducing the pigmentation pathway.
Melanotan II is cheaper to produce and more widely available in the RUO market. The MW difference between the two is approximately 1 Da — too small for standard-resolution MS to resolve reliably. HPLC differentiates them by retention time. Buying the wrong compound means receiving a peptide with additional MC1R-driven pigmentation effects and a potentially different safety profile, including the risk of hyperpigmentation that may not resolve after discontinuation.
If a vendor sells both PT-141 and Melanotan II, verify each compound independently through Peptigrity. Identical pricing between the two when PT-141 is at the bottom of the expected range is a signal to verify more carefully.
Frequently Asked Questions
What purity should research-grade PT-141 have?
≥98% HPLC from a third-party lab. HPLC is especially important for PT-141 because it differentiates the cyclic product from its linear precursor and from Melanotan II, which standard MS may not resolve. Cross-reference on peptigrity.com/lab-tests.
How much does research-grade PT-141 cost?
$30–80 for 10 mg. Vyleesi (prescription bremelanotide): ~$1,000/dose. Below $20 for 10 mg is suspicious. Compare across vendors on peptigrity.com/shops.
Is PT-141 the same as Vyleesi?
Same active molecule (bremelanotide, cyclic heptapeptide, MW ~1,025.2 Da). Different quality. Vyleesi is manufactured under cGMP with full FDA oversight for HSDD in premenopausal women (approved 2019). Research-grade PT-141 has no mandatory manufacturing standards — purity and identity must be verified independently through Peptigrity. Research-grade PT-141 is not a substitute for prescription Vyleesi.
Is PT-141 the same as Melanotan II?
No. PT-141 is derived from Melanotan II but is a distinct compound. PT-141 was engineered to reduce MC1R (pigmentation) activity while retaining MC3R/MC4R (CNS sexual arousal) activity. Melanotan II has broader receptor activity including skin tanning effects. MW difference is only ~1 Da — HPLC is more reliable than standard MS for distinguishing them.
Is PT-141 FDA-approved?
PT-141 (bremelanotide) is FDA-approved as Vyleesi for HSDD in premenopausal women (2019). This approval does not extend to research-grade PT-141 from RUO vendors. PT-141 is not on FDA Category 2. WADA prohibits it under S0 for competitive athletes.
For the complete buyer verification framework, see How to Verify Peptide Quality Before You Buy and What to Look for in a Peptide Shop: A Buyer's Checklist. Browse all peptide shops ranked by trust score.
This article is for educational and informational purposes only and does not constitute medical advice. PT-141 (bremelanotide) is FDA-approved as Vyleesi for a specific indication under prescription only. Research-grade PT-141 from RUO vendors is not equivalent to pharmaceutical-grade Vyleesi and has no mandatory manufacturing standards. Always consult a qualified healthcare provider before using any peptide or medication. Peptigrity is an independent review platform and does not sell, endorse, or recommend specific products or vendors.
